Melanoma Survivor on Her Way To Princeton With Her Sights Set for the U.S. Olympic Team
The summer before her fourth-grade year, Cate Sauer noticed what looked like a skin tag under her chin. After a…
05/05/2023
Melanoma Survivor on Her Way To Princeton With Her Sights Set for the U.S. Olympic Team
The summer before her fourth-grade year, Cate Sauer noticed what looked like a skin tag under her chin. After a…
|
05/03/2023
Shop the Black Ribbon Boutique in May
Since 2020, AIM at Melanoma has partnered with Bonfire.com to sell t-shirts that raise awareness of melanoma as well as…
|
05/01/2023
May is National Melanoma and Skin Cancer Awareness Month
Dear Friends, As most everyone in the melanoma community knows, May is National Melanoma and Skin Cancer Awareness Month. What…
|
04/26/2023
While You’re Spring Cleaning, Create Your Will Online for Free
Spring is synonymous with blooming flowers, longer days, and warmer weather, and we hope your part of the country is…
|
04/11/2023
The Unexpected Journey of Caring
Guests Donna Thomson and Dr. Zachary White discuss their book The Unexpected Journey of Caring. Becoming a caregiver is one…
|
03/14/2023
Transformation after Trauma
Our lives are filled with ups and downs, triumphs and tragedies, success and stress. The question is not whether we…
|
02/28/2023
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)– The applications are based on results from the Phase 3 CheckMate -76K trial,…
|
|
02/07/2023
Functional Nutrition for Cancer Survivors
In this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
|
01/27/2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
|
01/26/2023
A Letter From Our Vice President | January 2023
Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
|
Recent Posts
Nov. 14, 2023
Melanoma Cancer and Financial Toxicity
Oct. 31, 2023
National Family Caregiver Month
Oct. 23, 2023
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial
Oct. 15, 2023
Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
Oct. 13, 2023